Skip to content

Other Financing at other companies

ALN
Alnylam PharmaceuticalsALNY
-$9K
PTC Therapeutics logo
PTC TherapeuticsPTCT
$6.34M+39.4%

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$1.86B+468%

Profitability

See full
Operating margin-183.2%-13.5pp
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%
Debt / equity
Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's other financing.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Palvella Therapeutics's other financing?
Palvella Therapeutics (PVLA) reported other financing of $1.98M in Q1 2026.
What does other financing mean?
Miscellaneous financing cash flows not classified in specific line items.